Patents by Inventor Richard Cerione
Richard Cerione has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210317115Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.Type: ApplicationFiled: November 17, 2020Publication date: October 14, 2021Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
-
Patent number: 11013724Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently —NH—, —O—, —CH2—O—, —NH—CH2—, or —N(CH3)—CH2—, provided that when at least one of X1 and X2 is —CH2—O—, —NH—CH2—, or —N(CH3)—CH2— then the —CH2— is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and YType: GrantFiled: February 5, 2019Date of Patent: May 25, 2021Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Cornell UniversityInventors: Lee A. McDermott, Prema C. Iyer, Richard A. Cerione, William P. Katt
-
Patent number: 10987317Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.Type: GrantFiled: January 13, 2020Date of Patent: April 27, 2021Assignee: Cornell UniversityInventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
-
Patent number: 10889585Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.Type: GrantFiled: January 6, 2020Date of Patent: January 12, 2021Assignees: CORNELL UNIVERSITY, ITHACA COLLEGEInventors: Richard Cerione, Kristin Cerione, Clint Stalnecker, Scott Ulrich
-
Patent number: 10767212Abstract: The present technology relates to kidney-type glutaminase (GLS) proteins that have a phenylalanine to tryptophan substitution at the position corresponding to residue 322 of human glutaminase C (GAC), and methods of using such proteins to screen for compounds that bind to the activation loop of GLS and/or modulate glutaminase activity of GLS.Type: GrantFiled: September 25, 2017Date of Patent: September 8, 2020Assignee: Cornell UniversityInventors: Richard Cerione, Jon W Erickson, Clint A Stalnecker
-
Publication number: 20200216448Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.Type: ApplicationFiled: January 6, 2020Publication date: July 9, 2020Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
-
Publication number: 20200206149Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.Type: ApplicationFiled: January 13, 2020Publication date: July 2, 2020Inventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jiabin Wang
-
Patent number: 10532034Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.Type: GrantFiled: March 25, 2010Date of Patent: January 14, 2020Assignee: Cornell UniversityInventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
-
Patent number: 10526322Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.Type: GrantFiled: December 5, 2015Date of Patent: January 7, 2020Assignees: Cornell University, Ithaca CollegeInventors: Richard Cerione, Kristin Cerione, Clint Stalnecker, Scott Ulrich
-
Publication number: 20190298747Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.Type: ApplicationFiled: May 17, 2019Publication date: October 3, 2019Applicant: Cornell UniversityInventors: Hening Lin, Richard Cerione
-
Patent number: 10342814Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.Type: GrantFiled: September 7, 2012Date of Patent: July 9, 2019Assignee: CORNELL UNIVERSITYInventors: Hening Lin, Richard Cerione
-
Publication number: 20190167648Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently —NH—, —O—, —CH2—O—, —NH—CH2—, or —N(CH3)—CH2—, provided that when at least one of X1 and X2 is —CH2—O—, —NH—CH2—, or —N(CH3)—CH2— then the —CH2— is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and YType: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Cornell UniversityInventors: Lee A. McDermott, Prema C. Iyer, Richard A. Cerione, William P. Katt
-
Patent number: 10245254Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently —NH—, —O—, —CH2—O—, —NH—CH2—, or —N(CH3)—CH2—, provided that when at least one of X1 and X2 is —CH2—O—, —NH—CH2—, or —N(CH3)—CH2— then the —CH2— is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and YType: GrantFiled: October 1, 2015Date of Patent: April 2, 2019Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Cornell UniversityInventors: Lee A. McDermott, Prema C. Iyer, Richard A. Cerione, William P. Katt
-
Publication number: 20180100178Abstract: The present technology relates to GLS proteins that have a phenylalanine to tryptophan substitution at the position corresponding to residue 322 of human GAC, and methods of using such proteins to screen for compounds that bind to the activation loop of GLS and/or modulate glutaminase activity of GLS.Type: ApplicationFiled: September 25, 2017Publication date: April 12, 2018Inventors: Richard Cerione, Jon W Erickson, Clint A Stalnecker
-
Publication number: 20170362221Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.Type: ApplicationFiled: December 5, 2015Publication date: December 21, 2017Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
-
Publication number: 20170290815Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently —NH—, —O—, —CH2—O—, —NH—CH2—, or —N(CH3)—CH2—, provided that when at least one of X1 and X2 is —CH2—O—, —NH—CH2—, or —N(CH3)—CH2— then the —CH2— is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and YType: ApplicationFiled: October 1, 2015Publication date: October 12, 2017Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Cornell UniversityInventors: Lee A. McDermott, Prema C. Iyer, Richard A. Cerione, William P. Katt
-
Publication number: 20140213530Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: CORNELL UNIVERSITYInventors: Hening Lin, Richard Cerione
-
Publication number: 20130252983Abstract: A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed.Type: ApplicationFiled: September 12, 2011Publication date: September 26, 2013Applicant: CORNELL UNIVERSITYInventors: Kristin Wilson Cerione, Richard A. Cerione
-
Publication number: 20120220610Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.Type: ApplicationFiled: March 25, 2010Publication date: August 30, 2012Applicant: CORNELL UNIVERSITYInventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
-
Publication number: 20070123462Abstract: The present invention relates to a method of inhibiting beta-amyloid-induced death of neuronal cells in a subject by inhibiting human tissue transglutaminase in the subject under conditions effective to inhibit beta-amyloid-induced death of neuronal cells. Also disclosed are methods for identifying candidate compounds suitable for inhibiting beta-amyloid-induced death of neuronal cells in a subject by identifying compounds which are capable of binding to human tissue transglutaminase as candidate compounds suitable for inhibiting beta-amyloid-induced death of neuronal cells in a subject. The present invention also relates to compounds suitable for inhibiting beta-amyloid-induced death of neuronal cells in a subject, as well as methods for designing such compounds.Type: ApplicationFiled: November 16, 2006Publication date: May 31, 2007Applicant: Cornell Research Foundation, Inc.Inventors: Richard Cerione, Joseph Wakshlag, Marc Antonyak